Cargando…

Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants

BACKGROUND: Integrase strand transfer inhibitors (INSTIs) are the class of antiretroviral (ARV) drugs most recently approved by the FDA for the treatment of HIV-1 infections. INSTIs block the strand transfer reaction catalyzed by HIV-1 integrase (IN) and have been shown to potently inhibit infection...

Descripción completa

Detalles Bibliográficos
Autores principales:	Smith, Steven J., Zhao, Xue Zhi, Burke, Terrence R., Hughes, Stephen H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5956922/ https://www.ncbi.nlm.nih.gov/pubmed/29769116 http://dx.doi.org/10.1186/s12977-018-0420-7

Ejemplares similares

Synthetic Approaches to a Key Pyridone-carboxylic Acid Precursor Common to the HIV-1 Integrase Strand Transfer Inhibitors Dolutegravir, Bictegravir, and Cabotegravir
por: Mahajan, Pankaj S., et al.
Publicado: (2023)

HIV-1 Integrase Inhibitors with Modifications That Affect Their Potencies against Drug Resistant Integrase Mutants
por: Smith, Steven J., et al.
Publicado: (2021)

HIV-1 Integrase Strand Transfer Inhibitors with Reduced Susceptibility to Drug Resistant Mutant Integrases
por: Zhao, Xue Zhi, et al.
Publicado: (2016)

Integrase Strand Transfer Inhibitors Are Effective Anti-HIV Drugs
por: Smith, Steven J., et al.
Publicado: (2021)

Bicyclic 1-Hydroxy-2-oxo-1,2-dihydropyridine-3-carboxamide-Containing HIV-1 Integrase Inhibitors Having High Antiviral Potency against Cells Harboring Raltegravir-Resistant Integrase Mutants
por: Zhao, Xue Zhi, et al.
Publicado: (2014)

Drug resistant integrase mutants cause aberrant HIV integrations
por: Varadarajan, Janani, et al.
Publicado: (2016)

4-Amino-1-hydroxy-2-oxo-1,8-naphthyridine-Containing Compounds Having High Potency against Raltegravir-Resistant Integrase Mutants of HIV-1
por: Zhao, Xue Zhi, et al.
Publicado: (2014)

Long Dissociation of Bictegravir from HIV-1 Integrase-DNA Complexes
por: White, Kirsten L., et al.
Publicado: (2021)

Correction to 4-Amino-1-hydroxy-2-oxo-1,8-naphthyridine-Containing Compounds Having High Potency against Raltegravir-Resistant Integrase Mutants of HIV-1
por: Zhao, Xue Zhi, et al.
Publicado: (2014)

Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir
por: Oliveira, Maureen, et al.
Publicado: (2018)

A Pharmacokinetic Dose-Optimization Study of Cabotegravir and Bictegravir in a Mouse Pregnancy Model
por: Mohan, Haneesha, et al.
Publicado: (2022)

Effect of a High‐Fat Meal on the Pharmacokinetics of the HIV Integrase Inhibitor Cabotegravir
por: Patel, Parul, et al.
Publicado: (2018)

Structure-Guided Optimization of HIV Integrase Strand Transfer Inhibitors
por: Zhao, Xue Zhi, et al.
Publicado: (2017)

A Practical Approach to Bicyclic Carbamoyl Pyridones with Application to the Synthesis of HIV-1 Integrase Strand Transfer Inhibitors
por: Mahajan, Pankaj S., et al.
Publicado: (2023)

Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile
por: Tsiang, Manuel, et al.
Publicado: (2016)

A computational overview of integrase strand transfer inhibitors (INSTIs) against emerging and evolving drug-resistant HIV-1 integrase mutants
por: Sayyed, Sharif Karim, et al.
Publicado: (2023)

Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the In Vitro Potency of Cabotegravir or Rilpivirine
por: Jeffrey, Jerry L., et al.
Publicado: (2022)

1049. Weight Gain in Persons Living with HIV (PLWH) Treated with Bictegravir Compared to Other Integrase Strand Transfer Inhibitors
por: Fang, Michelle, et al.
Publicado: (2020)

875. Indirect Treatment Comparison of 48-Week Efficacy and Safety of Cabotegravir + Rilpivirine Long-Acting Every 2 Months to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Suppressed HIV-1 Infected Participants
por: Snedecor, Sonya J, et al.
Publicado: (2021)

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
por: Smith, Steven J., et al.
Publicado: (2014)

Development and validation of a multiplex UHPLC‐MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV
por: Courlet, Perrine, et al.
Publicado: (2020)

Bictegravir/Emtricitabine/Tenofovir Alafenamide Efficacy in Participants With Preexisting Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials
por: D'Antoni, Michelle L., et al.
Publicado: (2022)

HIV drug resistance against strand transfer integrase inhibitors
por: Anstett, Kaitlin, et al.
Publicado: (2017)

HIV Integrase Inhibitors Block Replication of Alpha-, Beta-, and Gammaherpesviruses
por: Yan, Zhipeng, et al.
Publicado: (2014)

Bictegravir and Metformin Drug-Drug Interaction in People with Human Immunodeficiency Virus (HIV)
por: Masich, Anne M., et al.
Publicado: (2023)

Selectivity for strand-transfer over 3′-processing and susceptibility to clinical resistance of HIV-1 integrase inhibitors are driven by key enzyme–DNA interactions in the active site
por: Métifiot, Mathieu, et al.
Publicado: (2016)

Cabotegravir
Publicado: (2022)

Prevalence of Primary Drug Resistance Against HIV-1 Integrase Inhibitors in Canada
por: Ji, Hezhao, et al.
Publicado: (2018)

Inhibition of Adipose Tissue Beiging by HIV Integrase Inhibitors, Dolutegravir and Bictegravir, Is Associated with Adipocyte Hypertrophy, Hypoxia, Elevated Fibrosis, and Insulin Resistance in Simian Adipose Tissue and Human Adipocytes
por: Ngono Ayissi, Kenza, et al.
Publicado: (2022)

HIV-1 Integrase-Targeted Short Peptides Derived from a Viral Protein R Sequence
por: Zhao, Xue Zhi, et al.
Publicado: (2018)

Reduced efficacy of HIV-1 integrase inhibitors in patients with drug resistance mutations in reverse transcriptase
por: Siedner, Mark J., et al.
Publicado: (2020)

Long-Acting Injectable Cabotegravir for HIV Prevention: What Do We Know and Need to Know about the Risks and Consequences of Cabotegravir Resistance?
por: Parikh, Urvi M., et al.
Publicado: (2022)

633. Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Efficacy in Participants with Pre-Existing Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials
por: D’Antoni, Michelle L, et al.
Publicado: (2020)

Pharmacokinetics of Bictegravir in Older Japanese People Living with HIV-1
por: Kawashima, Akira, et al.
Publicado: (2023)

Efficacy and Safety of Bictegravir-Based Regimen in Pregnant Women Living with HIV: A Case Report
por: Alsulami, Shaimaa, et al.
Publicado: (2022)

Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition
por: Fonner, Virginia A., et al.
Publicado: (2023)

1599. Real-World Efficacy of Long-Acting Cabotegravir and Rilpivirine in an Urban HIV Clinic
por: Perez, Sarah, et al.
Publicado: (2023)

Quantum Mechanical-Based Stability Evaluation of Crystal Structures for HIV-Targeted Drug Cabotegravir
por: Han, Yanqiang, et al.
Publicado: (2021)

Cabotegravir, the Long-Acting Integrase Strand Transfer Inhibitor, Potently Inhibits Human T-Cell Lymphotropic Virus Type 1 Transmission in vitro
por: Schneiderman, Bethany S., et al.
Publicado: (2022)

Comparison of metal-dependent catalysis by HIV-1 and ASV integrase proteins using a new and rapid, moderate throughput assay for joining activity in solution
por: Andrake, Mark D, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_08pp35savd8dov6g3882ssspn5